<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">cct4</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>CCT4</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Chaperonin Containing TCP1 Subunit 4 (Delta)</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>2p15</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>10382</td>
</tr>
<tr>
<td class="label">OMIM ID</td>
<td>605588</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000108771</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>P50991</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>539 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~58 kDa</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Description</td>
</tr>
<tr>
<td class="label">CCT enhancers</td>
<td>Increase chaperone activity</td>
</tr>
<tr>
<td class="label">Substrate stabilizers</td>
<td>Stabilize CCT substrates</td>
</tr>
<tr>
<td class="label">Gene therapy</td>
<td>Viral delivery of CCT subunits</td>
</tr>
<tr>
<td class="label">Combination therapy</td>
<td>With other chaperones</td>
</tr>
<tr>
<td class="label">Interactor</td>
<td>Type</td>
</tr>
<tr>
<td class="label">Other CCT subunits</td>
<td>Complex members</td>
</tr>
<tr>
<td class="label">Actin</td>
<td>Substrate</td>
</tr>
<tr>
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">cct4</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>CCT4</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Chaperonin Containing TCP1 Subunit 4 (Delta)</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>2p15</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>10382</td>
</tr>
<tr>
<td class="label">OMIM ID</td>
<td>605588</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000108771</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>P50991</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>539 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~58 kDa</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Description</td>
</tr>
<tr>
<td class="label">CCT enhancers</td>
<td>Increase chaperone activity</td>
</tr>
<tr>
<td class="label">Substrate stabilizers</td>
<td>Stabilize CCT substrates</td>
</tr>
<tr>
<td class="label">Gene therapy</td>
<td>Viral delivery of CCT subunits</td>
</tr>
<tr>
<td class="label">Combination therapy</td>
<td>With other chaperones</td>
</tr>
<tr>
<td class="label">Interactor</td>
<td>Type</td>
</tr>
<tr>
<td class="label">Other CCT subunits</td>
<td>Complex members</td>
</tr>
<tr>
<td class="label">Actin</td>
<td>Substrate</td>
</tr>
<tr>
<td class="label">Tubulin</td>
<td>Substrate</td>
</tr>
<tr>
<td class="label">Hsp70</td>
<td>Co-chaperone</td>
</tr>
<tr>
<td class="label">Hsp90</td>
<td>Proteostasis network</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
The CCT4 gene encodes the delta subunit of the Chaperonin Containing TCP1 (CCT) complex, also known as TRiC (TCP-1 Ring Complex). CCT4 is one of eight distinct subunits that comprise this essential hetero-oligomeric chaperone system required for the proper folding of cytoskeletal proteins including actin and tubulin[@yaffe2002].
The CCT complex is evolutionarily conserved and represents the major cytosolic chaperone system in eukaryotes. Its function is particularly critical in cells with high protein turnover and complex morphology, such as neurons, where proper folding of cytoskeletal components is essential for synaptic function, axonal transport, and overall cellular integrity[@willison1999].
The CCT4 gene spans approximately 12 kb and consists of 12 exons. The protein is expressed ubiquitously with particularly high levels in brain tissue.
The CCT complex is a barrel-shaped chaperone consisting of eight distinct subunits[@lopez1997]:
CCT4 contains characteristic chaperonin domains:
CCT4 participates in the CCT chaperone cycle[@kubota2005]:
The CCT complex folds numerous substrates[@frydman2001]:
CCT dysfunction contributes to AD through multiple pathways[@grantham2020]:
Tau pathology:
CCT in PD pathogenesis[@brasseur2020]:
Alpha-synuclein:
CCT involvement in ALS[@gottstein2022]:
Protein aggregation:
CCT is essential for synaptic processes[@spong2019]:
CCT supports neuronal development:
CCT in glial cells:
CCT4 expression:
CCT4 interacts with:
CCT4 encodes the delta subunit of the CCT complex, an essential cytosolic chaperone required for folding of actin, tubulin, and numerous other substrates. CCT dysfunction contributes to neurodegenerative diseases including AD, PD, and ALS through effects on cytoskeletal integrity, synaptic function, and overall protein homeostasis. Therapeutic targeting of CCT offers potential for neuroprotection, though challenges remain in achieving specific modulation[@stadelmann2010][@valpuesta2002][@spong2019].
CCT4 operates within the broader proteostasis network:
The CCT chaperone cycle is highly regulated:
CCT has sophisticated substrate recognition:
CCT function declines with age:
Age-related CCT decline contributes to:
The following diagram shows the key molecular relationships involving cct4 discovered through SciDEX knowledge graph analysis:
CCT4 is a delta-subunit of the TRiC/CCT (Tcp1 Ring Complex / Chaperonin Containing Tcp1) complex, a ~1-MDa cylindrical chaperonin that folds actin, tubulin, and dozens of other cytoskeletal substrates in an ATP-dependent manner inside the eukaryotic cytosol. The TRiC complex consists of eight different CCT subunits (CCT1–CCT8), each contributing a distinct interface for substrate recognition; CCT4 specifically facilitates folding of β-actin and certain tubulin isotypes through a mechanism in which the substrate enters the central cavity in a partially folded state and undergoes multiple rounds of encapsulation and ATP-driven conformational cycling until native structure is achieved. Mutations in CCT subunit genes cause hereditary sensory neuropathy type I, demonstrating that impaired cytoskeletal protein quality control is sufficient to trigger neurodegeneration. In Alzheimer's disease, the TRiC complex participates in tau metabolism: proper CCT function is required for microtubule assembly downstream of tau phosphorylation events, and proteomic studies show altered CCT subunit abundance in AD brain tissue. CCT4 dysfunction leads to accumulation of misfolded cytoskeletal proteins, triggering ER stress and activating the unfolded protein response. The TRiC complex also interacts with the HSP90 system through shared substrates and cooperative client delivery, providing a failsafe for proteins that escape HSP90-mediated folding. Therapeutic strategies targeting CCT function include allosteric activators of the TRiC ATPase cycle and compounds that stabilize CCT-substrate interactions. PMID: 41104595 PMID: 31964905 PMID: 23612981 PMID: 8661059 PMID: 12874111
The following diagram shows the key molecular relationships involving cct4 discovered through SciDEX knowledge graph analysis: